Ascendis Pharma A (ASND) Equity Income (2018 - 2026)

Ascendis Pharma A has disclosed Equity Income across 9 years of filings, most recently posting $12.0 million for Q1 2026.

• Equity Income for Q1 2026 came in at $12.0 million, up 142.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $140442.4 (up 100.32% YoY), and the FY2025 annual result was $19.0 million, up 188.56% from the prior year.
• Equity Income came in at $12.0 million for Q1 2026 at Ascendis Pharma A, up from $1.5 million in the prior quarter.
• In the past five years, Equity Income ranged from a high of $12.0 million in Q1 2026 to a low of -$28.0 million in Q1 2025.
• The 5-year median for Equity Income is -$4.9 million (2024), against an average of -$5.0 million.
• Across the five-year window, Equity Income slumped 578.1% in 2024 and jumped 142.93% in 2026, its largest moves.
• Ascendis Pharma A's Equity Income stood at -$8.1 million in 2022, then jumped by 61.27% to -$3.1 million in 2023, then slumped by 55.4% to -$4.9 million in 2024, then surged by 131.62% to $1.5 million in 2025, then jumped by 676.36% to $12.0 million in 2026.
• The last three Equity Income figures came in at $12.0 million (Q1 2026), $1.5 million (Q4 2025), and -$8.8 million (Q3 2025), per Business Quant data.